Kirin’s L. lactis Plasma Beverage Enters Singapore Market! “KIRIN IMMUSE” to Launch on July 20

TOKYO, July 8, 2026 - Kirin Holdings Co., Ltd. will launch “KIRIN IMMUSE Yoghurt Flavour,” a beverage containing Kirin’s proprietary ingredient L. lactis Plasma, in Singapore on July 20. As Kirin accelerates the global expansion of L. lactis Plasma, this marks the first entry into the Singapore market for a beverage featuring L. lactis Plasma developed by Kirin*1.
1 First entry into Singapore for a beverage containing L. lactis Plasma developed by Kirin Holdings.

In recent years, demand for beverages that emphasize health value has been expanding in Singapore, driven by a growing health consciousness among consumers. Products offering added value such as daily health maintenance and nutritional supplementation have been leading market growth*2.
In addition, the introduction of the Nutri-Grade system*3, which visualizes nutritional information in an easy-to-understand manner, has further heightened health awareness in daily purchasing behaviour.
2 Euromonitor International, “Health and Wellness Soft Drinks” (Singapore, 2019–2024).
3 A nutrition grading system introduced by the Singapore government that classifies beverages and certain foods into four grades (A–D) based on sugar and saturated fat content, displaying the grade on the front of packages to help consumers make healthier choices.

Against this market backdrop, Kirin will launch “KIRIN IMMUSE Yoghurt Flavour,” a product developed specifically for Singapore that allows consumers to easily incorporate healthy habits into their daily lives. This product contains 100 billion L. lactis Plasma and has been developed in line with local health awareness and lifestyles. It is positioned as the first step in the full-scale development of Kirin’s L. lactis Plasma business in Southeast Asia.

As part of this strategy, Kirin has partnered with “Fullerton Health*4”, a provider of healthcare services in Southeast Asia, to promote sales and information dissemination. Initially, sales of the product will begin through the company’s digital platform, the “Fullerton Health Marketplace*5” creating touchpoints with health-conscious consumers. Looking ahead, we will further leverage the company’s membership base, corporate client network, and digital tools such as apps to expand awareness and promote the adoption of healthy lifestyle habits.
4 Official website of Fullerton Health: Fullerton Health (https://www.fullertonhealth.com/)
5 Digital Sales Platform: Fullerton Health Marketplace (https://marketplace.fullertonhealthtech.com/#/home)

Under its long-term vision “Innovate2035!”, the Kirin Group aims to “energize the world as a leading CSV*6 company that continues to create innovation through the power of people and technology.” Toward this goal, Kirin positions beverages containing L. lactis Plasma as a core category within its Health Science business and will continue to expand product offerings in this category, primarily in Southeast Asia, to support people’s health.
6 Creating Shared Value: combined added value for consumers as well as for society at large.

1．Product name	“KIRIN IMMUSE Yoghurt Flavour”
2．Sales area	Singapore
3．Date of release	Monday, July 20, 2026
4．Container	200ml plastic bottle 200ml plastic bottle (6-bottle pack) 200ml plastic bottle (24-bottle pack)

About Kirin Holdings

Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain.

Under its long-term vision “Innovate2035!”, the Kirin Group is focused on creating value that encourage behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being.

The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*6, while pursuing sustainable, long-term growth in corporate value.

GALLERY